Head-to-head · WeighScore
Vitara RX vs Henry Meds
The verdict
Vitara RX takes it — 86/100 to 76/100.
Vitara RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Sub-$100 semaglutide and $149 tirzepatide — both molecules, verified and nationwide.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Vitara RX | Henry Meds |
|---|---|---|
| WeighScore | 86/100 | 76/100 |
| Grade | B | C |
| Scorecard rank | #6 | #25 |
| Semaglutide | $99/mo | $249/mo |
| Tirzepatide | $149/mo | $349/mo |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #6 · B
Strengths
- $99 sema / $149 tirz — bottom-quartile pricing
- Both molecules, all 50 states
- LegitScript-verified
Where it loses points
- Injection-only, no oral route
- Labs/monitoring not detailed
- Newer, thinner track record
Graded #25 · C
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.